Company Quick10K Filing
Q Biomed
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 15 $27
10-Q 2019-07-19 Quarter: 2019-05-31
10-Q 2019-04-17 Quarter: 2019-02-28
10-K 2019-03-07 Annual: 2018-11-30
S-1 2018-10-25 Public Filing
10-Q 2018-10-15 Quarter: 2018-08-31
10-Q 2018-07-16 Quarter: 2018-05-31
10-Q 2018-04-16 Quarter: 2018-02-28
10-K 2018-02-28 Annual: 2017-11-30
10-Q 2017-10-18 Quarter: 2017-08-31
10-Q 2017-07-19 Quarter: 2017-05-31
10-Q 2017-04-14 Quarter: 2017-02-28
10-K 2017-02-28 Annual: 2016-11-30
10-Q 2016-10-17 Quarter: 2016-08-31
10-Q 2016-07-07 Quarter: 2016-05-31
10-Q 2016-04-22 Quarter: 2016-02-29
10-K 2016-03-11 Annual: 2015-11-30
10-Q 2015-10-20 Quarter: 2015-08-31
10-Q 2015-07-15 Quarter: 2015-05-31
10-Q 2015-04-14 Quarter: 2015-02-28
10-K 2015-02-27 Annual: 2014-11-30
10-Q 2014-10-15 Quarter: 2014-08-31
10-Q 2014-07-15 Quarter: 2014-05-31
10-Q 2014-04-11 Quarter: 2014-02-28
8-K 2020-01-15 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-12-05 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-11-27 Leave Agreement, Sale of Shares
8-K 2019-11-20 Regulation FD, Exhibits
8-K 2019-10-11 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-09-05 Enter Agreement
8-K 2019-08-28 Enter Agreement, Sale of Shares
8-K 2019-08-13 Enter Agreement, Sale of Shares
8-K 2018-12-28 Other Events
8-K 2018-11-23 Enter Agreement, Regulation FD, Exhibits
8-K 2018-11-01 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-09-21 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2018-02-13 Sale of Shares, Exhibits
8-K 2018-01-29 Enter Agreement, Regulation FD, Exhibits

Q Biomed Financials

QBIO Metrics, Comps, Filings

Annual | Quarterly

Business

We are a biotechnology acceleration and development company focused on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. We aim to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. We have acquired or licensed assets in oncology, vascular disease, and rare orphan diseases that address unmet medical needs in large markets Currently, we have a portfolio therapeutic products, including two FDA approved products, Metastron ™ (approved in 22 countries) and its generic, Strontium 89 Chloride, a radiopharmaceutical for the non-opiate treatment of metastatic cancer bone pain, and several development stage products including: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma as well as other MAN assets in development for infectious diseases, cardiovascular diseases and kidney disease. We aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle. We expect to benefit from early positioning in illiquid and/or less well known privately-held assets, thereby enabling us to capitalize on valuation growth as these assets move forward in their development.

(i)license and acquire pre-commercial innovative life sciences assets in different stages of development and therapeutic areas from academia or small private companies;

(ii)license and acquire FDA approved drugs and medical devices with limited current and commercial activity; and


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
SMG Industries (SMGI) 28,311 22% -16.0 -34% 8,009 7,185 5,104 1,117 -2,706 -1,904 30,494
Sanuwave Health (SNWV) 28,298 59% -3.1 -517% 1,513 17,869 1,548 906 -7,818 -9,193 28,143
Two Rivers Water & Farming (TURV) 28,133 43% -4.6 -24% 30,687 21,475 86 37 -7,320 -6,266 29,055
United Cannabis (CNAB) 28,061 23% -2.6 -73% 15,085 9,919 13,490 3,056 -10,992 -10,194 26,934
Parallax Health Sciences (PRLX) 27,960 340% -3.2 -684% 1,361 7,846 61 207 -9,311 -9,186 28,958
Oroplata Resources (ORRP) 27,896 -3.7 -8,991% 93 4,547 0 0 -8,382 -7,632 27,880
Algodon (VINO) 27,776 52% -6.1 -77% 6,714 5,354 2,135 1,102 -5,141 -4,514 27,408
Peerstream (PEER) 27,066 76% 8.7 6% 21,368 4,193 17,880 13,543 1,183 2,579 22,424
Cannabics Pharmaceuticals (CNBX) 27,044 30% 13.2 10% 19,772 454 11 3 2,010 2,010 26,551
Q Biomed (QBIO) 27,006 -4.5 -1,090% 682 5,043 0 0 -7,437 -6,777 30,497
Social Life Network (WDLF) 26,793 -178% -4.3 623,088,800% 244 91 -163 -6,231 -6,230 26,764
Quest Solution (QUES) 26,415 24% 67.2 -7% 40,147 34,630 70,375 17,202 -2,685 355 23,850
Envision Solar (EVSI) 26,339 -4% -7.9 -37% 10,092 2,606 5,272 -237 -3,746 -2,577 20,421
Quaint Oak Bancorp (QNTO) 26,322 1.2 1% 284,877 260,049 0 0 2,259 8,082 10,068
Cadus (KDUS) 26,288 -55.5 -1% 38,250 654 0 0 -434 -432 23,980
CBAK Energy Technology (CBAK) 26,236 -10% 3.6 -1% 118,341 112,167 24,513 -2,351 -1,038 2,438 8,712
Uniroyal Global (UNIR) 26,162 17% 6.0 1% 69,196 56,355 96,597 16,083 829 5,088 30,598
Crexendo (EXE) 26,054 0% 46.8 6% 6,618 3,583 13,229 0 370 501 23,453
Micropac Industries (MPAC) 25,912 110% 7.7 7% 27,721 2,124 19,521 21,392 2,009 1,821 14,048
Achison (ACHI) 25,674 920.5 34% 57 12 0 0 19 28 25,666

Balance Sheet ($'000)2014-11-302016-11-302017-11-302018-11-30
Cash132,3958252,684
Accounts Receivable
Inventory
PP&E
Assets131,4698273,197
Accounts Payable1
Long-Term Debt23202,873
Liabilities13,5124713,303
Stockholders' Equity11-2,043356-106
Income Statement ($'000)2014-11-302016-11-302017-11-302018-11-30
Revenue0
Cost of Revenue
Gross Profit
R&D1,3143,1003,238
SG&A85,0329,2725,782
Tax0000
Net Income-381,100-14,542990
Cash Flow ($'000)2014-11-302016-11-302017-11-302018-11-30
Cash Operating-37-1,5455,600-6,451
Cash Investing-500
Cash Financing252,8834,9418,810